INCY Incyte Corp.
As of 12:25:00 PM ET
Loading chart…
- Open
- $118.36
- Previous close
- $120.39
- Day range
- 118.36 – 121.21
- 52-week range
- 89.25 – 132.60
- Volume
- 40.3K
- Avg volume (3M)
- 1.6M
- Market cap
- $24.4B
- P/E (TTM)
- 61.42
- EPS (TTM)
- $1.96
- Beta
- 0.74
- Dividend yield
- 0.00%
- Next earnings
- —
- Ex-dividend
- —
- Sector
- Healthcare
About Incyte Corp.
Incyte Corp. is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The company’s current portfolio centers on hematology, oncology, and inflammation and autoimmunity, with products and programs aimed at treating cancers, blood disorders, and immune-mediated conditions. Incyte Corp. develops both small-molecule medicines and biologics, and its marketed therapies support patients with a range of specialty disease areas, including dermatology and rare hematologic disorders. The company also maintains a pipeline of clinical-stage candidates across its core therapeutic franchises, reflecting its role as a research-driven developer of targeted treatments. Headquartered in Wilmington, Delaware, Incyte Corp. serves healthcare markets in the United States and internationally through its commercial and development activities.
| Quarter | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Oct 29, 2026(after close) | −$3.87 | −$3.60 | −7.0% |
| Jul 16, 2026(after close) | $1.10 | $1.17 | +6.4% |
| Jun 11, 2026(after close) | −$0.33 | −$0.09 | −72.7% |
| Apr 28, 2026(after close) | $1.34 | $1.81 | +35.1% |
INCY doesn’t pay a dividend.
INCY news and filings
Loading filings…
Filings from SEC EDGAR.